

IN THE CLAIMS:

Please amend the claims as follows:

Cancel claim 90 without prejudice.

Sub 17
68. (Twice Amended) A method of screening for the presence of a malignancy characterized by an aberrant level of a Notch protein or [Notch derivative] a molecule having antigenicity of a Notch protein in a patient, comprising measuring the level of expression of a Notch protein or of a [Notch derivative] molecule capable of being bound by an anti-Notch antibody in a sample derived from the patient, in which an increase or decrease in the Notch protein or [derivative] molecule in the patient sample relative to the level found in such a sample from an individual not having the malignancy indicates the presence of the malignancy in the patient.

22
69. (Twice Amended) A method of screening for the presence of a malignancy characterized by increased expression of a Notch protein or of a [Notch derivative] molecule capable of being bound by an anti-Notch antibody, comprising measuring the level of expression of a Notch protein or of a [Notch derivative] molecule capable of being bound by an anti-Notch antibody, in a sample containing or suspected of containing malignant cells from a patient, in which an increase in expression of a Notch protein or of a [Notch derivative] molecule capable of being bound by an anti-Notch antibody, in the sample, relative to said level found in an analogous sample of non-malignant cells indicates the presence of the malignancy in the patient.

In claim 74, line 2, delete "derivative" and insert therefor --molecule-- .

91. (Amended) A method of screening for the presence of a disease or disorder of the nervous system characterized by an aberrant level of a Notch protein or [Notch derivative] molecule having antigenicity of a Notch protein in a patient, comprising measuring the level of expression of a Notch protein or of a [Notch derivative] molecule capable of being bound by an anti-Notch antibody in a sample derived from the patient, in which an increase or decrease in the Notch protein or [derivative] molecule in the patient sample relative to the level found in such a sample from an individual not having the disease or disorder indicates the presence of the disease or disorder in the patient.

92. (Amended) A method of screening for the presence of a benign dysproliferative disorder characterized by an aberrant level of a Notch protein or [Notch derivative] molecule having antigenicity of a Notch protein in a patient, comprising measuring the level of expression of a Notch protein or of a [Notch derivative] molecule capable of being bound by an anti-Notch antibody in a sample derived from the patient, in which an increase or decrease in the Notch protein or [derivative] molecule in the patient sample relative to the level found in such a sample from an individual not having the disorder indicates the presence of the disorder in the patient.